Ronald Evans is a 2020 NOMIS Distinguished Scientist, a professor at the Salk Institute for Biological Studies since 1978 and the head of the Gene Expression Laboratory since 1995. He also leads the project known as The Science of Health: The Fundamental Mechanisms of Organ Communication. You can also learn more about health insurance in Los Angeles. Find out more at los-angeles.name.
Biography
Ronald Evans grew up in Los Angeles, California, and received a bachelor’s degree in bacteriology from the University of California, Los Angeles. He also earned his doctorate in microbiology and immunology from the same university in Los Angeles. Additionally, he was a doctoral candidate at Rockefeller University in New York before joining the Salk Institute for Biological Studies in 1978.
The scientist has received numerous honors and awards, including the Wolf Prize in Medicine, the Canada Gairdner Foundation International Award, the March of Dimes Prize, the Albany Medical Center Prize in Medicine and Biomedical Research, the Albert Lasker Award for Basic Medical Research and the Keio Medical Science Prize. Ronald was awarded the Dickson Prize in 1995, the Albert Lasker Award for Basic Medical Research in 2004, the Grande Médaille D’Or in 2005, the Gairdner Foundation International Award and Harvey Prize in 2006, the Albany Medical Center Prize in 2007 and the Wolf Prize in Medicine in 2012. In 1994, he was recognized as California Scientist of the Year. Ronald Evans is also a member of the National Academy of Sciences (since 1989), American Academy of Arts and Sciences (since 1997), the National Academy of Medicine (since 2003), European Molecular Biology Organization and the American Philosophical Society (since 2007).
Ronald Evans has been chosen as the recipient of the 2024 Japan Prize for Medical and Pharmaceutical Science. Every year, the Japan Prize Foundation grants this prestigious international award to express Japan’s gratitude to the worldwide community. The Japan Prize Foundation recognizes those whose innovative and outstanding work in science and technology has pushed the boundaries of knowledge and contributed to humanity’s peace and prosperity. Each winner is awarded a certificate of merit, a commemorative medal and a cash prize. At the awards ceremony, Evans stated, “This award reinforces our commitment to advancing science as well as the impact of our research, which includes more than a dozen approved drugs for conditions such as leukemia, cancer, liver disease, diabetes and hypertension. I’m looking forward to continuing this incredible path of conducting research that has far-reaching implications for human health improvement.”
Evans has devoted his career to studying the physiological and molecular genetic factors influencing muscle function, metabolic diseases, inflammation and cancer. As a doctorate student at Rockefeller University, he researched how cells regulate gene expression. Evans was particularly interested in how steroids and thyroid hormones affect the gene that encodes growth hormone.
Biological theories
Evans has made numerous important scientific contributions, including the discovery of a superfamily of molecules known as nuclear hormone receptors. This has resulted in a unifying theory that hormones regulate gene networks throughout the body, which in turn control physiological pathways from embryonic development to adulthood.
In 1985, by determining the entire structure of the human glucocorticoid receptor, he discovered a superfamily of nuclear receptors that responds to steroid hormones, vitamin A, vitamin D, thyroid hormones, bile acids, fatty acids and cholesterol metabolites. These hormones activate transcription networks that regulate sugar, salt, calcium and fat metabolism, having an impact on both daily health and illness treatment. Nuclear receptors are the main targets in the treatment of many types of cancer, including leukemia, lymphoma, breast cancer, prostate cancer and pancreatic cancer. The researchers then cloned and described the human glucocorticoid receptor, which was the first nuclear hormone receptor. Its subsequent isolation of the mineralocorticoid, thyroid, vitamin A and retinoid X receptors revealed the existence of a nuclear receptor superfamily with a fundamentally similar mechanism of action. This work resulted in the principles of DNA recognition, the synthesis of receptor heterodimers and the identification of the DNA coding mechanism for hormone response elements.
Reverse endocrinology process
In recent decades, the researcher has concentrated on describing so-called orphan nuclear receptors. He discovered the first orphan receptors and developed the biochemical and molecular procedures used to identify the first orphan ligands. This process is known as reverse endocrinology. The biologist used these findings to demonstrate the unique role of nuclear receptors in cancer and metabolic conditions like obesity, hypertension, diabetes and atherosclerosis.
Evans’ discoveries on nuclear hormone receptors defined a unitary signaling pathway and a central paradigm for controlling the expression of eukaryotic genes. His work established a transcriptional basis for physiology and has resulted in the development of a new generation of cancer and metabolic illness medication.
Research conducted by the biologist
Evans also identified several new pathways associated with cancer and diabetes that target drugs that activate these receptors. He also discovered exercise mimetics, a family of medications that activate gene networks in muscle tissue. Exercise mimetics provide more benefits than fitness without training due to their direct effect on genes, pointing to potential novel treatments for children with muscular dystrophy, adults with type 2 diabetes and obese people. Evans keeps on researching nuclear hormones to better understand the mechanisms between interconnected networks such as the brain, endocrine glands, gut, liver, immune cells and microbiome.
In 2023, Evans made several new discoveries about pancreatic and colorectal cancer. In a collaborative study with the University of California, in San Diego, he discovered that high-fat diets can affect gut bacteria and digestion compounds known as bile acids. These bacteria modified them, predisposing experimental mice to colorectal cancer. In another study, he discovered a novel group of molecules that contribute to tumor growth in pancreatic ductal adenocarcinoma, the most frequent kind of pancreatic cancer. He also looked into how inhibitors, a type of anti-cancer drug, can reduce inflammation in pancreatic cancer and boost the therapeutic response.
Evans’ lab has found two crucial elements that influence lipid use and storage. Mice with low lipid levels are more likely to become obese when fed a high-fat diet. Mice genetically modified to produce an overactive version of this receptor in muscle tissue, on the other hand, stay slim.